LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.

LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.

Item
http://www.wikidata.org/entity/Q34194729
BDNF mediates the neuroprotective effects of positive AMPA receptor modulators against MPP+-induced toxicity in cultured hippocampal and mesencephalic slicesGlutamate receptor ion channels: structure, regulation, and functionNeuregulin-1β prevents Ca(2+) overloading and apoptosis through PI3K/Akt activation in cultured dorsal root ganglion neurons with excitotoxicity induced by glutamate.Activation of ERK1/2 and PI3K/Akt by IGF-1 on GAP-43 expression in DRG neurons with excitotoxicity induced by glutamate in vitro.Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 micePharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers.New medications for drug addiction hiding in glutamatergic neuroplasticity.SMi 4th Annual Conference on Neurodegenerative Disorders: a focus on Alzheimer's and Parkinson's disease.Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease.Calcium-permeable AMPA receptors containing Q/R-unedited GluR2 direct human neural progenitor cell differentiation to neurons.Catalytic Asymmetric Mannich Reactions with Fluorinated Aromatic Ketones: Efficient Access to Chiral β-Fluoroamines.Synaptic regulation of affective behaviors; role of BDNFGlutamate receptors as therapeutic targets for Parkinson's disease.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Therapeutic potential of targeting glutamate receptors in Parkinson's disease.Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's diseaseInitial biological qualification of SBDP-145 as a biomarker of compound-induced neurodegeneration in the rat.
P2860

LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.

Item
http://www.wikidata.org/entity/Q34194729
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
LY503430, a novel alpha-amino- ...... models of Parkinson's disease.
@ast
LY503430, a novel alpha-amino- ...... models of Parkinson's disease.
@en
LY503430, a novel alpha-amino- ...... models of Parkinson's disease.
@nl
type
label
LY503430, a novel alpha-amino- ...... models of Parkinson's disease.
@ast
LY503430, a novel alpha-amino- ...... models of Parkinson's disease.
@en
LY503430, a novel alpha-amino- ...... models of Parkinson's disease.
@nl
prefLabel
LY503430, a novel alpha-amino- ...... models of Parkinson's disease.
@ast
LY503430, a novel alpha-amino- ...... models of Parkinson's disease.
@en
LY503430, a novel alpha-amino- ...... models of Parkinson's disease.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
LY503430, a novel alpha-amino- ...... models of Parkinson's disease
@en
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921